Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WEE1 | P30291 | 2/20 | 0.66 |
| ▸ | CSF1R | P07333 | 3/20 | 0.65 |
| ▸ | CDK4 | P11802 | 10/20 | 0.65 |
| ▸ | CCND3 | P30281 | 8/20 | 0.65 |
| ▸ | CCND1 | P24385 | 7/20 | 0.65 |
| ▸ | CCND2 | P30279 | 7/20 | 0.65 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.65 |
| ▸ | MARK3 | P27448 | 1/20 | 0.65 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.65 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.65 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.65 |
| ▸ | MARK1 | Q9P0L2 | 1/20 | 0.65 |
| ▸ | AURKA | O14965 | 3/20 | 0.63 |
| ▸ | CDK1 | P06493 | 3/20 | 0.63 |
| ▸ | SRC | P12931 | 2/20 | 0.63 |
| ▸ | KDR | P35968 | 2/20 | 0.63 |
| ▸ | INSR | P06213 | 1/20 | 0.63 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.63 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.63 |
| ▸ | FLT1 | P17948 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7714624 | 0.96 | CDK4 (0.70) | WEE1CSF1RCDK4CCND3CCND1 | |
| SCHEMBL7708879 | 0.95 | CSF1R (0.71) | WEE1CSF1RCDK4CCND3CCND1 | |
| SCHEMBL7713224 | 0.89 | CDK4 (0.65) | CDK4CCND3CCND1CCND2NUAK1 | |
| SCHEMBL11977083 | 0.88 | CDK4 (0.69) | CSF1RCDK4CCND3CCND1CCND2 | |
| SCHEMBL7713223 | 0.87 | CDK4 (0.68) | WEE1CSF1RCDK4CCND3CCND1 | |
| SCHEMBL11977115 | 0.86 | CDK4 (0.70) | CSF1RCDK4CCND3CCND1CCND2 | |
| SCHEMBL7713061 | 0.85 | CDK4 (0.71) | CDK4CCND3CCND1CCND2NUAK1 | |
| SCHEMBL11977089 | 0.84 | CSF1R (0.59) | WEE1CSF1RCDK4CCND3CCND1 | |
| SCHEMBL7710738 | 0.84 | CDK4 (0.70) | CDK4CCND3CCND1CCND2NUAK1 | |
| SCHEMBL7710732 | 0.84 | CDK4 (0.74) | CSF1RCDK4CCND3CCND1CCND2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | NOVARTIS AG (CH) | 2018-07-26 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | NOVARTIS AG (CH) | 2016-01-14 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2013-02-07 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-8324225-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2012-12-04 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| WO-2011130232-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR AND AN MTOR INHIBITOR FOR TREATING CANCER | NOVARTIS AG (CH) | 2011-10-20 | — | — | WO | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | ASTEX THERAPEUTICS LTD. | 2009-12-24 | — | — | US | disclosed |
| WO-2007140222-A2 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035336-A1 | COMBINATION COMPRISING A CYCLIN DEPENDENT KINASE 4 OR CYCLIN DEPENDENT KINASE (CDK4/6) INHIBITOR FOR TREATING CANCER | CDK4, CDK6, CDK8 | WEE1 87/4885CSF1R 2421/4885CDK4 1/4885 |
| US-20090318441-A1 | Pyrrolopyrimidine Compounds and Their Uses | PRKDC, TK2, PNKP | WEE1 318/4885CSF1R 4378/4885CDK4 4/4885 |
| US-20180207163-A1 | Methods and compositions for treating solid tumors and other malignancies | CDK4, CDK6, MTOR | WEE1 66/4885CSF1R 3135/4885CDK4 1/4885 |
| US-20160008367-A1 | Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer | CDK4, CDK6, CDKL4 | WEE1 100/4885CSF1R 2341/4885CDK4 1/4885 |
| US-20120207763-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | PRKDC, TK2, PNKP | WEE1 318/4885CSF1R 4378/4885CDK4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.